Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinical Trial Enrollment

- PMLiVE

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

- PMLiVE

Paving the way for the HCP omnichannel experience: a guide for medical affairs

By Stephen Jones

- PMLiVE

NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments

The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund

- PMLiVE

EU approves bluebird bio’s CALD gene therapy Skysona

CALD is a progressive and fatal neurodegenerative disease that overwhelmingly affects males

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel

Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence

- PMLiVE

AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront

The candidate – suvratoxumab – is ready for phase 3 clinical evaluation for the prevention of pneumonia

Bayer symbol

Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy

In 2019, Bayer bought out its private equity partner Versant Ventures and founders in BlueRock Therapeutics for $240m

Take part in research with Oxford University Press (OUP)

The Research Team at OUP is currently looking for professionals working in healthcare communication, education, marketing or advertising to take part in some upcoming research.

Oxford University Press

- PMLiVE

BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform

German biotech company said the acquisition will boost its presence in the US

- PMLiVE

Maxwellia works with 11 London for social promotion of first ever OTC contraceptive pill

We’re excited to announce that we are now working with pioneering British pharma company Maxwellia to help launch Lovima®, a contraceptive pill to be available in pharmacies without the need...

11 London

- PMLiVE

Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’

Kriya is aiming to advance lower cost gene therapies with ‘broader applications’ for disease such as type 1 and type 2 diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links